TABLE 2.
Summary of Lmr loci that control pathological parameters in CcS-16 and potential candidate genes
| Chromosome | Locus | Marker | Position (cM) | Phenotypic effect of allelesb | Parameter(s) controlled | Candidate gene(s) |
|---|---|---|---|---|---|---|
| 2 | Lmr14 | D2Mit389 | 50.3 | C < S | Hepatomegaly, splenomegaly | |
| D2Mit102 | 52.5 | C < S | Hepatomegaly, splenomegaly | |||
| D2Nds3 | 73.0 | C < S | Hepatomegaly, splenomegaly | Il1 complex (IL-1 complex) | ||
| D2Mit283 | 83.5 | C < S | Hepatomegaly, splenomegaly | |||
| D2Mit51 | 95.5 | C < S | Hepatomegaly, splenomegaly | |||
| 11 | Lmr15 | D11Mit242 D11Mit37 | 31.0 47.0 | C > S C > S | Hepatomegaly Hepatomegaly | nos2 (nitric oxide synthase 2) scya (small inducible cytokine) |
| 18 | Lmr13 | D18Mit120 | 16.0 | C < S | Lesion size | ?a |
| D18Mit35 | 24.0 | C < S | Lesion size |
a
?, unknown.
b
C < S, effect of STS allele aggravates pathology; C > S, effect of STS allele alleviates pathology.